Superior limbic keratoconjunctivitis
Other Names for this Disease
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.
eye disease which affects the superior bulbar conjunctiva (the clear layer that covers the eyeball, over the sclera) and tarsal conjunctiva (the clear layer that lines the eyelids), as well as the superior limbic aspect of the cornea (the area above the cornea). It is commonly found in women 20-70 years of age. The signs and symptoms include burning, redness and irritation and tend to develop slowly over a period of 1 to 10 years. Vision usually remains intact. While the underlying cause of SLK remains unknown, there appears to be an association between the condition and thyroid abnormalities (usually hyperthyroidism), contact lens wear, graft versus host disease, and preservatives from ophthalmologic medications.Superior limbic keratoconjunctivitis (SLK) is a chronic and recurrent
Last updated: 7/24/2012
- Kabat AG. Lacrimal occlusion therapy for the treatment of superior limbic keratoconjunctivitis. Optom Vis Sci. 1998; http://www.ncbi.nlm.nih.gov/pubmed/9798210. Accessed 7/23/2012.
- Oakman JH. Superior Limbic Keratoconjunctivitis. Medscape Reference. August 26, 2011; http://emedicine.medscape.com/article/1194578-overview. Accessed 7/23/2012.
- Papaliodis GN. Superior Limbic Keratoconjunctivitis. The Ocular Immunology and Uveitis Foundation. http://www.uveitis.org/docs/dm/superior_limbal_keratoconjunctivitis.pdf. Accessed 7/23/2012.
On this page
- Medscape Reference provides information on this topic. You may need to register to view the medical textbook, but registration is free.
- Orphanet is a European reference portal for information on rare diseases and orphan drugs. Access to this database is free of charge.
- PubMed is a searchable database of medical literature and lists journal articles that discuss Superior limbic keratoconjunctivitis. Click on the link to view a sample search on this topic.